

# PRESS RELEASE



## Hansa Biopharma to host conference call to provide interim results for the first quarter of 2020 and business update

Lund, Sweden April 15, 2020. Hansa Biopharma will publish its interim report for January-March 2020 at 8:00 a.m. CET on April 28, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call.

To participate in the telephone conference, please use the dial-in details provided below:

### Dial-in numbers for participants:

SE: +46 8 50 55 83 54

UK: +44 333 300 92 69

US: +1 833 249 84 06

The webcast will be available on <https://hansa.eventcdn.net/2020q1/>

The information was submitted for publication, through the contact person set out below, at 8:00 a.m. (CET) on April 15, 2020.

### Contact information

Klaus Sindahl  
Head of Investor Relations  
Hansa Biopharma  
M: +46 (0) 709-298 269  
E: klaus.sindahl@hansabiopharma.com

### About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.

Hansa Biopharma  
Scheelevägen 22  
SE- 223 63 Lund, Sweden  
Phone: +46 46 16 56 70  
[www.hansabiopharma.com](http://www.hansabiopharma.com)

Nasdaq OMX Stockholm  
Ticker: HNSA  
ISIN: SE 0002148817